Atualização no tratamento das afecções oculares por herpes simples vírus

Atualização no tratamento das afecções oculares por herpes simples vírus


Paulo Elias C. Dantas


Arquivos Brasileiros de Oftalmologia

versão impressa ISSN 0004-2749versão On-line ISSN 1678-2925

Arq. Bras. Oftalmol. vol.61 no.4 São Paulo ago. 1998


1 US Departament of Health and Human Services. External ocular infections and inflamatory disease. ln: Vision research: a national plan 1983-1987 (NIH publication n 83-2472), Washington, DC, National Eye Institute, 1983.
2 Liesegang TJ. A community study of ocular herpes simplex. Curr Eye Res 1991; 10(Suppl):111-5.
3 Remeijer L, Doornembal P, Gerards DJM et al. Newly acquired herpes simplex virus keratitis after penetrating keratoplasty. Ophthalmol 1997;104:648-52.
4 Lee SY, Laibson PR. Medical management of herpes simplex ocular infections. Int Ophthalmol Clin 1996;36:85-97.
5 Sterk CC, Jager MJJ, Berg MS. Recurrent herpetic keratitis in penetrating keratoplasty. Documenta Ophthalmol 1995;90:29-33.
6 Cockerham GC, Krafft AE, McLean IW. Herpes simplex virus in primary graft failure. Arch Ophthalmol 1997; 115:586-9.
7 Kaufman HE, Martola EL, Dohlman C. Use of 5-iodo-2-deoxyuridine (IDU) in the treatment ofherpes simplex keratitis. Arch Ophthalmol 1962;68:223-38.
8 Colin J. Superficial herpes simplex keratitis - a double-blind comparative triai of acyclovir and idoxiuridine. Nouv Press Med 1981; 10:2969-75.
9 La Lau C, Oosterhuis J, Versteeg J et al. Acyclovir and trifluorothymidine in herpetic keratitis. A multicenter trial. Br J Ophthalmol 1982;66:506-8.
10 Collum LMS, Logan P, McAulife-Curtin D et al. Randomised double-blind trial of acyclovir and adenina arabinoside in herpes simplex amoeboid corneal ulceration. Br J Ophthalmol 1985;69:847-50.
11 Erlich KS, Mills J, Chatis P et al. Acyclovir resistant herpes simplex virus infection in patients with AIDS. N Eng J Med 1989;320:293-6.
12 Sonkin PL, Baratz KH, Frothinghan R et al. Acyclovir resistant herpes simplex keratouveitis after penetraing keratoplasty. Ophthalmology 1992;99: 1805-8.
13 Markham A, Falch D. Gancyclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994;48:455-84.
14 Shiota H, Naito T, Mimura Y. Antiherpes simplex virus effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine in rabbit cornea. Curr Eye Res 1987;6:241-5.
15 Trousdale MD, Nesburn AB, Willey DE et al. Efficacy of BW759 9-(1,3-dihydroxi-2-propoxymethyl) guanine against herpes simplex virus type 1 keratitis in rabbits. Curr Eye Res 1984;3:1007-15.
16 Hoh HB, Harley C, Claone C at al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: A multicenter study. Br J Ophthalmol 1996;80:140-3.
17 Colin J, Hoh HB, Easty DL et al. Gancyclovir ophthalmic gel (Virgan 0,15%) in the treatment of herpes simplex keratitis. Cornea 1997;16(4):393-9.
18 Spector SA, Weigenst T, Pollard RB et al. A randomised controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-63.
19 Maudgal PC, Missotten L, De Clercq E et al. (E)-5-(2-bromovinyl)-2-deoxyuridine in the topical treatment of herpes simplex keratitis. Graeffes Arch Clin Exp Ophthalmol 1981;216:261-8.
20 Maudgal PC, Dieltiens M, De Clercq E et al. Topical bromovinyldeoxiuridine treatment ofherpes simplex keratitis. Doc Ophthalmol Proc Ser 1985;44:247-56.
21 Panda A, Das GK, Khokhar S, Rao V. Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. Can J Ophthalmol 1995;30:256-8.
22 Weller S, Blun MR, Donnetti T et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharm Ther 1993;54:595-605.
23 Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infection. Drugs 1996;52:754-72.
24 Pue HD, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993;4:47-55.
25 Luber AD, Flaherty JF Jr. Famciclovir for treatment ofherpesvirus infections. Ann Pharrnacother 1996;30:978-85.
26 Cumpacker C. The pharmacological profile of famciclovir. Semin Dermatol 1996;15:14-26.
27 Isaacs A, Lindenmann J. Virus interference. 1. The interferon. Proc R Soc Lond B 1957;147:258-67.
28 Sundmacher R, Cantell K, Hang P, Newmann-Haefelin D. Interpheron-Prophylaxe von Dendritica-Rezidiven bei lokale Steroidtherapie. Ber Dtsch Ophthalmol Ger 1977;75:344-6.
29 Sundmacher R, Cantell K, Hang P, Newmann-Haefelin D. Role of debridement and interferorn in the treatment of dendritic keratitis. Albrech v Graefes Arch Klin Exp Ophthalmol 1978;207:77-82.
30 Coster DJ, Falcon MG, Cantell K, Jones BR. Clinical experience of human leukocyte interferon in the management of herpetic keratitis. Trans Ophthalmol Soc UK 1977;97:327-9.
31 Sundmacher R, Cantell K, Newmann-Haefeli D. Combination therapy of dendritic keratitis with trifluorothymidine and interferon. Lancet 1978;ii:687.
32 Colin J, Chastel C, Renard G, Cantell K. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir. Am J Ophthalmol 1983;95:346-8.
33 De Konieg EWJ, van Bijsterveld OP, Cantell K. Combination therapy for dendritic keratitis with acyclovir and alpha-interferon. Arch Ophthalmol 1983;101:1866-8.
34 Minkovitz JB, Pepose JS. Topical interferon alpha-2 treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosupressed patient. Cornea 1995;14:326-30.
35 Santoro MG, Benedetto G, Carruba E et al. Prostaglandin A compounds as antiviral agents. Science 1980;209: 1032-4.
36 O'Brien WJ, Taylor JL, Ankel H, Sitenga G. Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis. Antimicrob Agents Chemother 1996;40:2327-31.
37 Shiota H, Nitta K, Naito T et al. Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers. Br J Ophthalmol 1996:80:413-5.
38 Shiota H, Nitta K, Naito T et al. Effect of carbocyclic oxetanocin on herpetic keratitis. Chemother 1992;40:841-2.
39 Klenk HD, Garten W. Host cell proteases controlling virus pathogenicity. Trends Microbiol 1994;2:39-43.
40 Aoki H, Akaike T, Abe K et al. Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type 1 in vitro and in vivo. Antimicrob Agents Chemother 1995;39:846-9.
41 Brandt CR, Spencer B, Imesch P et al. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model oh herpes simplex virus type 1 ocular disease. Antimicrobiol Agents Chemother 1996;40:1078-84.
42 Kaufman HE, Varnell ED, Wright GE et al. Effect of 9-(4-hidroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, on clinicai recurrences of ocular herpetic keratitis in squirrel monkeys. Antivirai Res 1996;33:65-72.
43 Gebbhardt BM, Wright GE, Xu H et al. 9-(4-hidroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, suppresses herpes virus reactivation in mice. Antiviral Res 1996;30:87-94.
44 Gebbhardt BM, Kaufman HE. Propanolol supresses reactivation of herpesvirus. Antiviral Res 1995;27(3):255-61.
45 Meduri R, Campos E, Scorolli L et ai. Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 1996;9:61-6.
46 Estrada-Parra S, Chávez-Sánchez R, Ondarza-Aguillera R et al. Immunotherapy with transfer factor of recurrent herpes simplex type 1. Arch Med Res 1995;26:s87-92.
47 De Maria A, Tundo P, Romao A, Grima P. Anti-HSV-1 herpes vaccination by Lupidon H: Preliminary results. In Advances in mucosal immunology, ed. by J. Mestecky et ai, Plennum Press, New York 1995; 1599-600.
48 Staats HF, Oakes JE, Lausch RN. Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets of asialo GM 1 + cells. J Virol 1991;65:6008.
49 Inoue Y, Oh JO, Minasi P. Protective effect of anti-glycoprotein D antibody on herpetic chorioretinitis in newborn rabbits. Curr Eye Res 1991;10:159.
50 Gamus D, Romano A, Rubinstein M, Savion N. Moderation ofherpetic stromal keratitis by basic fibroblast growth factor. Exp Eye Res 1996;63: 1-8.